Skip to content
Triangle logo TriangleGet started
← Neuroendocrine Tumor

NCT02084134 · STUDY IN CONTEXT

Peri-Operative Steroid Management in Patients

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Adrenal insufficiency was defined by a 30 or 60 min cortisol \< 18 during a cosyntropin stimulation test

Source null

→

secondary · POSTED

Patient charts were reviewed to identify patients who were discharged on prednisone

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-neuroendocrine-tumor
nct id
NCT02084134
trial label
Peri-Operative Steroid Management in Patients
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
2
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    outcome key
    om-0000
    source section id
    NCT02084134-om-0000
    source outcome index
    0
    endpoint
    Number of Participants With Adrenal Insufficiency
    endpoint definition
    Adrenal insufficiency was defined by a 30 or 60 min cortisol \< 18 during a cosyntropin stimulation test
    time origin
    6 weeks following surgery
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    outcome key
    om-0001
    source section id
    NCT02084134-om-0001
    source outcome index
    1
    endpoint
    Percentage of Patients Discharged on Glucocorticoids
    endpoint definition
    Patient charts were reviewed to identify patients who were discharged on prednisone
    time origin
    1 day (Day of hospital discharge)
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Steroid Treatment Arm
    regimen
    Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg hydrocortisone: 100mg at the time of surgery dexamethasone: 0.5mg every 6 hours for a total of four doses
    analyzed count
    19
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02084134-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Non-steroid Treatment
    regimen
    Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
    analyzed count
    17
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02084134-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Steroid Treatment Arm
    regimen
    Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg hydrocortisone: 100mg at the time of surgery dexamethasone: 0.5mg every 6 hours for a total of four doses
    analyzed count
    19
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02084134-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Non-steroid Treatment
    regimen
    Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
    analyzed count
    17
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02084134-om-0001#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    harm key
    EG000
    source section id
    NCT02084134-ae
    event group key
    EG000
    event group label
    Steroid Treatment Arm
    serious affected
    0
    serious at risk
    23
    other affected
    0
    other at risk
    23
    frequency threshold
    2
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-neuroendocrine-tumor
    nct id
    NCT02084134
    harm key
    EG001
    source section id
    NCT02084134-ae
    event group key
    EG001
    event group label
    Non-steroid Treatment
    serious affected
    1
    serious at risk
    20
    other affected
    0
    other at risk
    20
    frequency threshold
    2
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice